4D Molecular Therapeutics (FDMT) Net Income (QoQ) (2020 - 2026)
4D Molecular Therapeutics (FDMT) Net Income (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -626.73% |
| Dec 31, 2025 | 120.98% |
| Sep 30, 2025 | 4.46% |
| Jun 30, 2025 | -81.81% |
| Mar 31, 2025 | 2.20% |
| Dec 31, 2024 | 35.15% |
| Sep 30, 2024 | -71.52% |
| Jun 30, 2024 | -16.36% |
| Mar 31, 2024 | -18.11% |
| Dec 31, 2023 | -13.71% |
| Sep 30, 2023 | 43.28% |
| Jun 30, 2023 | -4.02% |
| Mar 31, 2023 | -62.78% |
| Dec 31, 2022 | 36.00% |
| Sep 30, 2022 | -38.25% |
| Jun 30, 2022 | -3.31% |
| Mar 31, 2022 | -26.08% |
| Dec 31, 2021 | 44.72% |
| Sep 30, 2021 | -340.36% |
| Jun 30, 2021 | 74.88% |